All In MedTech

FDA Clearance Tracker · P230035-S006

AGENT Paclitaxel-Coated Balloon Catheter

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 11, 2026

Approved

Time to decision

265 days

Received May 22, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P230035-S006
Device name
AGENT Paclitaxel-Coated Balloon Catheter
Applicant location
Maple Grove, MN
Received
May 22, 2025
Decided
Feb 11, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P230035

Device type

Device class
Class III

Every decision under product code OOB

FDA's approval statement

As written in FDA's record.

a manufacturing site change to include Boston Scientific Ltd., located at Ballybrit Business Park, Galway, Ireland, for drug coating manufacturing, packaging and labeling for the Agent Monorail Paclitaxel Coated Balloon Catheter

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.